Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with, or have had a return or worsening of, a blood cancer (either a myeloid or lymphoid type) that involves a specific gene change called an FGFR1 rearrangement, identified using the WHO-2016 diagnostic guidelines.
• People with a general health and activity level that falls within an acceptable range as assessed by their doctor (a scale called the ECOG score — confirm specific score requirements with the trial site).
• People whose doctors estimate they are expected to live for at least 12 weeks.
• People who are willing and able to follow all study procedures and attend required follow-up appointments.

Who may not be able to join:

• People who have previously received a bone marrow or stem cell transplant from a donor, or who have previously taken the drug ponatinib.
• People who have HIV, or who currently have an active hepatitis B or hepatitis C infection.
• People who are pregnant, planning to become pregnant, or currently breastfeeding.
• People who are unlikely to be able to complete all required study visits, procedures, or follow-up appointments.
• People who have any other health condition that, in the opinion of the trial doctor, could put them at risk or affect how the study drug is evaluated.

Important: Always verify eligibility with the trial site directly before applying.